Health Kick Podcast: Cynata Therapeutics entering into major stem cell clinical catalysts

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast.

In this episode, Tim catches up with Cynata Therapeutics (ASX:CYP) CEO Dr Kilian Kelly to dive into the stem cell industry as the company enters the most pivotal phase in its history.

The clinical-stage company focused on regenerative medicines has a unique process to manufacture a scarce kind of cell at a previously unprecedented scale, so Tim and Kilian go into the technology, its development and place in the wider industry, the wealth of data it already has on hand, and what lies ahead as the company enters into two major clinical catalysts.

This podcast was developed in collaboration with Cynata Therapeutics, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.